Healthcare: 3 Genomics Stocks Revolutionizing Healthcare And Why Alnylam's New Deal Didn't Excite Investors

Here's why a $1 billion deal with Regeneron failed to spark a rally in Alnylam shares. Also, will genetic discovery be our generation's biggest trend? If so, Illumina, bluebird bio, and Invitae could be top stocks to watch. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter